Affinity Asset Advisors, LLC Glycomimetics Inc Transaction History
Affinity Asset Advisors, LLC
- $579 Million
- Q3 2024
A detailed history of Affinity Asset Advisors, LLC transactions in Glycomimetics Inc stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 142,300 shares of GLYC stock, worth $44,113. This represents 0.06% of its overall portfolio holdings.
Number of Shares
142,300Holding current value
$44,113% of portfolio
0.06%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding GLYC
# of Institutions
36Shares Held
17.8MCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA9.54MShares$2.96 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.67MShares$827,7640.0% of portfolio
-
Siren, L.L.C. New York, NY1.97MShares$609,1850.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny781KShares$242,1410.0% of portfolio
-
Black Rock Inc. New York, NY723KShares$224,1870.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $16.3M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...